CN108251377B - 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 - Google Patents
利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 Download PDFInfo
- Publication number
- CN108251377B CN108251377B CN201810041514.XA CN201810041514A CN108251377B CN 108251377 B CN108251377 B CN 108251377B CN 201810041514 A CN201810041514 A CN 201810041514A CN 108251377 B CN108251377 B CN 108251377B
- Authority
- CN
- China
- Prior art keywords
- mef
- cells
- feeder
- culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 16
- 108091023040 Transcription factor Proteins 0.000 title claims abstract description 15
- 102000040945 Transcription factor Human genes 0.000 title claims abstract description 15
- 108091007416 X-inactive specific transcript Proteins 0.000 title claims abstract description 13
- 108091035715 XIST (gene) Proteins 0.000 title claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 131
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims abstract description 52
- 229960004857 mitomycin Drugs 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000012010 growth Effects 0.000 claims description 20
- 238000001638 lipofection Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000007710 freezing Methods 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 230000001605 fetal effect Effects 0.000 claims description 11
- 238000002123 RNA extraction Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 238000010839 reverse transcription Methods 0.000 claims description 10
- 238000010257 thawing Methods 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000007664 blowing Methods 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000010802 RNA extraction kit Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 230000001079 digestive effect Effects 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 2
- 210000001728 clone cell Anatomy 0.000 claims description 2
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 238000011369 optimal treatment Methods 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 210000000130 stem cell Anatomy 0.000 abstract description 4
- 241000283690 Bos taurus Species 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 3
- 229930192392 Mitomycin Natural products 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 210000001671 embryonic stem cell Anatomy 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 19
- 239000010410 layer Substances 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 7
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 4
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 4
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Component | 1× | 20× |
SYBR(2×) | 10μL | 200μL |
cDNA | 1μL | 20μL |
Nuclear-Free water | 4μL | 80μL |
15μL |
Component | 1× | 9× |
Primer F+R(10μM) | 0.8μL | 7.2μL |
Nuclear-Free water | 4.2μL | 37.8μL |
5μL |
Component | 1× | 16× |
SYBR(2×) | 10μL | 16μL |
cDNA | 1μL | 16μL |
Nuclear-Free water | 4μL | 64μL |
15μL |
Component | 1× | 5× |
Primer F+R(10μM) | 0.8μL | 4μL |
Nuclear-Free water | 4.2μL | 21μL |
5μL |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810041514.XA CN108251377B (zh) | 2018-01-16 | 2018-01-16 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810041514.XA CN108251377B (zh) | 2018-01-16 | 2018-01-16 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108251377A CN108251377A (zh) | 2018-07-06 |
CN108251377B true CN108251377B (zh) | 2021-08-27 |
Family
ID=62741343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810041514.XA Active CN108251377B (zh) | 2018-01-16 | 2018-01-16 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108251377B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114134103A (zh) * | 2021-11-30 | 2022-03-04 | 北京中因科技有限公司 | 一种高效获得高活力iPSCs单克隆的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004028339A2 (en) * | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
WO2009061442A1 (en) * | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
CN102741394A (zh) * | 2009-10-16 | 2012-10-17 | 斯克里普斯研究所 | 多能细胞的诱导 |
CN103114075B (zh) * | 2013-01-18 | 2014-11-12 | 内蒙古大学 | 一种牛滋养层干细胞建系方法 |
CN106754729A (zh) * | 2016-12-31 | 2017-05-31 | 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 | 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5460054B2 (ja) * | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ras特異的細胞障害性化合物およびその使用法 |
WO2007062243A2 (en) * | 2005-11-28 | 2007-05-31 | Choongwae Pharma Corporation | Serum-free expansion of cells in culture |
BRPI0918337A2 (pt) * | 2008-12-19 | 2017-05-30 | Abbott Lab | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso |
CN109750000A (zh) * | 2017-11-06 | 2019-05-14 | 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 | 利用XistTale抑制性转录因子R6制备新型动物细胞系R6-MEFs方法及用途 |
-
2018
- 2018-01-16 CN CN201810041514.XA patent/CN108251377B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004028339A2 (en) * | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
WO2009061442A1 (en) * | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
CN102741394A (zh) * | 2009-10-16 | 2012-10-17 | 斯克里普斯研究所 | 多能细胞的诱导 |
CN103114075B (zh) * | 2013-01-18 | 2014-11-12 | 内蒙古大学 | 一种牛滋养层干细胞建系方法 |
CN106754729A (zh) * | 2016-12-31 | 2017-05-31 | 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 | 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法 |
Non-Patent Citations (3)
Title |
---|
KDM4B-mediated reduction of H3K9me3 and H3K36me3 levels improves somatic cell reprogramming into pluripotency;Jingwei Wei等;《Scientific Reports》;20170808;第7卷;第1-14页 * |
Xist Tale R-dTFs来源的小鼠iPS细胞系的建立及多能性鉴定;梁延峰;《中国优秀硕士学位论文全文数据库(电子期刊)基础科学辑》;20170215(第2期);A006-52 * |
Xist Tale R-dTFs来源的小鼠iPS细胞系的建立及多能性鉴定;梁延峰等;《中国畜牧兽医学会动物繁殖学分会第十八届学术研讨会暨中日韩第四届动物繁殖学术交流会论文集》;20160818;第148页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108251377A (zh) | 2018-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Golestaneh et al. | Pluripotent stem cells derived from adult human testes | |
LU502505B1 (en) | Immortalized yak rumen epithelial cell line and construction method thereof | |
US20110236978A1 (en) | Reprogramming cells toward a pluripotent state | |
Mohamadi et al. | Comparison of colony formation in adult mouse spermatogonial stem cells developed in Sertoli and STO coculture systems | |
Kang et al. | Improving cell survival in injected embryos allows primed pluripotent stem cells to generate chimeric cynomolgus monkeys | |
WO1995010599A1 (en) | Embryonic stem cell-like cells | |
CN101984050B (zh) | 用于产生诱导多能干细胞(iPS)的细胞类型及其制备方法和应用 | |
CN109837307B (zh) | 建立含外源染色体的胚胎干细胞的方法 | |
CN112553140B (zh) | 一种雌性鸡原始生殖细胞体外扩增培养体系及其应用 | |
CN106754729B (zh) | 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法 | |
CN108251377B (zh) | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 | |
Uhlin et al. | Integration free derivation of human induced pluripotent stem cells using Laminin 521 matrix | |
CN106085951B (zh) | 一种建立可持续传代的树鼩精原干细胞细胞系的方法 | |
CN114276984B (zh) | 雌性生殖干细胞转分化至功能精子的方法及应用 | |
Ibtisham et al. | The optimized condition for the isolation and in vitro propagation of mouse spermatogonial stem cells | |
JP2010200676A (ja) | 多能性幹細胞の選別方法 | |
CN113881623B (zh) | 一种利用孤雌激活的孤雌胚胎干细胞体外分化形成卵子的方法 | |
CN114369567B (zh) | 牛扩展多能性胚胎干细胞的建系方法及培养液 | |
US9976118B2 (en) | Method for inducing tailored pluripotent stem cells using extract of plant stem cells or plant dedifferentiated stem cells, and pluripotent stem cells produced by means of the method | |
Bai et al. | Previously claimed male germline stem cells from porcine testis are actually progenitor Leydig cells | |
WO2013159313A1 (zh) | 一种动物胚胎干细胞系及其制备方法和应用 | |
Tobias et al. | Derivation and culture of canine embryonic stem cells | |
CN118256424B (zh) | 基于胚胎分割技术建立非人灵长类自体胚胎干细胞的方法 | |
KR102180733B1 (ko) | 탈지우유를 유효성분으로 포함하는 줄기세포 분리용 조성물 | |
CN116463379A (zh) | 一种将iPSC从多能态向全能态转变的TBX3载体系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180712 Address after: 011517 Jinle Economic Zone, Helingeer City, Hohhot, the Inner Mongolia Autonomous Region. The intersection of Jinsheng road and East Valley Road of Sheng Le modern service area Applicant after: INNER MONGOLIA SAIKEXING LIVESTOCK BREEDING AND SEED INDUSTRY BIOTECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. Applicant after: INNER MONGOLIA SK-XING BREEDING BIOTECHNOLOGY (Group) Co.,Ltd. Address before: 011517 Jinle Economic Zone, Helingeer City, Hohhot, the Inner Mongolia Autonomous Region. The intersection of Jinsheng road and East Valley Road of Sheng Le modern service area Applicant before: INNER MONGOLIA SAIKEXING LIVESTOCK BREEDING AND SEED INDUSTRY BIOTECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Jindun Inventor after: Li Xihe Inventor before: Zhang Jindun Inventor before: Li Xihe Inventor before: Liang Yanfeng Inventor before: Fan Lihong |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190611 Address after: 010020 No. 235 West University Road, Saihan District, Hohhot City, Inner Mongolia Autonomous Region Applicant after: INNER MONGOLIA University Applicant after: INNER MONGOLIA SAIKEXING LIVESTOCK BREEDING AND SEED INDUSTRY BIOTECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. Applicant after: INNER MONGOLIA SK-XING BREEDING BIOTECHNOLOGY (Group) Co.,Ltd. Address before: 011517 Jinle Economic Zone, Helingeer City, Hohhot, the Inner Mongolia Autonomous Region. The intersection of Jinsheng road and East Valley Road of Sheng Le modern service area Applicant before: INNER MONGOLIA SAIKEXING LIVESTOCK BREEDING AND SEED INDUSTRY BIOTECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. Applicant before: INNER MONGOLIA SK-XING BREEDING BIOTECHNOLOGY (Group) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |